Presseinformationen weltweit an Journalisten und Leser verbreiten
. Financial highlights Direct sales of MagnetOs rose 75% from CHF 6.9 million to CHF 12.1 million in 2022. Total revenue from medical devices CHF 13.3 million, up from CHF 8.3 million Revenue from collaboration CHF 4.7 million vs CHF Mehr
Publications in peer reviewed Journal of Immunology and Regenerative Medicine and Clinical Oral Implants Research Adds to body of evidence for MagnetOs, using data from human and animal models Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation Mehr
Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the appointment of Daniel Geiger as Chief Financial Officer (CFO) ad interim, effective February 17, 2023. Daniel Geiger succeeds Michael Grau, who will handover Mehr
. First investigational trial of drug-biologic bone graft for spinal fusion No drug-related Serious Adverse Events (SAEs) reported in randomized stage of the trial Enrollment of additional 20 patients for second non-randomized stage underway Potential to address a major commercial Mehr
Preliminary data shows 78% fusion rate vs 42% for autograft and 55-71% for other synthetic bone grafts Level 1 clinical study compares MagnetOs Granules to local autograft in patients undergoing posterolateral lumbar fusion First of five randomized controlled Level 1 Mehr
Total product sales grow to CHF 8.9 million in the first nine months of 2022 Reaches major milestone of 10,000 patients treated with MagnetOs Positive first clinical data from planned randomized controlled trials Full commercial launch of MagnetOs Flex Matrix Mehr
. MagnetOs Flex Matrix recognized as exemplary and innovative spine surgery product Rounds out MagnetOs portfolio to provide more solutions for surgeons Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, today announces that Mehr
First clinical data from five planned randomized controlled trials Show favorable fusion rate compared to autograft Launch of MagnetOs Flex Matrix expands perioperative options for surgeons Schlieren (Zurich), Switzerland, 11 October, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a Mehr
Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has appointed Chris Fair as Chief Operating Officer (COO). Mr. Fair is a leader in the musculoskeletal and regenerative medicine industry with Mehr
Kuros Biosciences AG (SIX:KURN) a leader in next generation bone graft technologies, announced today the successful completion of a CHF 6.0 million capital increase through a private placement of 3,750,000 new shares of Kuros with a par value of CHF Mehr